Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | ECE1 | P42892 | 6/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SI | P14410 | 2/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8418352 | 1.00 | ACE (0.46) | ACEECE1LTA4HMGAMGAA | |
| SCHEMBL8418341 | 0.86 | MMP9 (0.39) | ECE1MGAMGAASIMGAM2 | |
| SCHEMBL8420365 | 0.86 | MMP9 (0.39) | ECE1MGAMGAASIMGAM2 | |
| SCHEMBL8418335 | 0.83 | GPR84 (0.54) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL8415721 | 0.81 | MMP2 (0.42) | MGAMGAASIMGAM2MEN1 | |
| SCHEMBL8984863 | 0.77 | MEN1 (0.49) | ACEECE1MGAMGAASI | |
| SCHEMBL13528266 | 0.76 | KMT2A (0.50) | MGAMGAASIMGAM2KMT2A | |
| SCHEMBL15290795 | 0.75 | HDAC3 (0.49) | ECE1MGAMGAASIMGAM2 | |
| SCHEMBL8525238 | 0.74 | MEN1 (0.57) | ACEECE1MEN1KMT2AMAPT | |
| SCHEMBL5281197 | 0.74 | MEN1 (0.57) | ACEECE1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335726-B2 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | NGLY1, LSS, NRDC | ACE 2884/4885ECE1 3407/4885LTA4H 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.